HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination (2007)
- Authors:
- USP affiliated authors: ANDRADE, JURANDYR MOREIRA DE - FMRP ; SILVA, ALFREDO RIBEIRO DA - FMRP
- Unidade: FMRP
- DOI: 10.1186/1471-2407-7-36
- Subjects: NEOPLASIAS MAMÁRIAS (PROGNÓSTICO); ANTINEOPLÁSICOS; EXPRESSÃO GÊNICA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: BMC Cancer
- ISSN: 1471-2407
- Volume/Número/Paginação/Ano: v. 7, n. 36, on-line, 2007
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
TIEZZI, Daniel G. et al. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer, v. 7, n. 36, 2007Tradução . . Disponível em: https://doi.org/10.1186/1471-2407-7-36. Acesso em: 24 abr. 2024. -
APA
Tiezzi, D. G., Andrade, J. M. de, Ribeiro-Silva, A., Zola, F. E., Marana, H. R. C., & Tiezzi, M. G. (2007). HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer, 7( 36). doi:10.1186/1471-2407-7-36 -
NLM
Tiezzi DG, Andrade JM de, Ribeiro-Silva A, Zola FE, Marana HRC, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination [Internet]. BMC Cancer. 2007 ; 7( 36):[citado 2024 abr. 24 ] Available from: https://doi.org/10.1186/1471-2407-7-36 -
Vancouver
Tiezzi DG, Andrade JM de, Ribeiro-Silva A, Zola FE, Marana HRC, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination [Internet]. BMC Cancer. 2007 ; 7( 36):[citado 2024 abr. 24 ] Available from: https://doi.org/10.1186/1471-2407-7-36 - HER2 overexpression predicts survival in stage II and III breast cancer patients treated with neoadjuvant docetaxel plus epirubicin
- Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases with review of the literature
- Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases
- HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin
- Metastases to the breast from extramammary malignancies: a clinicopathologic study of 12 cases and review of the literature
- HER2 overexpression predicts survival in stage II and III breast cancer patients treated with neoadjuvant docetaxel plus epirubicin
- Apoptosis induced by neodjuvant chemotherapy in breast cancer
- Induction of apoptosis predicts response to neoadjuvant chemotherapy in locally advanced breast cancer
- Tumor infiltrating lymphocytes are related to lymph node metastasis in patients with T1-T2 breast cancer
- Induction of apoptosis predicts response to neoadjuvant chemotherapy in locally advanced breast cancer
Informações sobre o DOI: 10.1186/1471-2407-7-36 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
